Authors
Latest:
Serial Liquid Biopsies Allow for Tracking of Resistance Mutations in GI CancersPashtoon M. Kasi, MBBS, MD, MS, clinical assistant professor of internal medicine, University of Iowa Carver College of Medicine, discusses how serial testing via liquid biopsies in patients with gastrointestinal cancers can provide oncologists with a better picture of the patient’s condition and potential acquired mechanisms of resistance.
Latest:
The Emerging Role of Genetic Testing in Colorectal CancerPashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
Latest:
Dr. Pat Whitworth on the Importance of the Luminal Subtype in Breast CancerWhitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype.
Latest:
Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 YearsA new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.
Latest:
Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDSPatricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Latest:
Questions That Remain Regarding Combination, Sequencing With PARP InhibitorsPatricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
Latest:
The Role of Antiangiogenic Therapy in Previously Treated CRCAngiogenesis is a critical factor in the propagation and metastasis of many tumor types, including colorectal cancer.
Latest:
Dr. Patrick Borgen on Breast Cancer Becoming More a Medical Disease Than SurgicalPatrick Borgen, MD, says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Latest:
Turning the Tide on Opioid Prescribing PracticesIn 2017 there was a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost. Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally. Two recent retrospective studies found that in patients undergoing surgery for early non–small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.
Latest:
Dr. Patrick Johnston on A Combination of Belinostat with Standard CHOP Chemotherapy in T-Cell LymphomaPatrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.
Latest:
Current and Emerging Immunotherapeutic Strategies in MelanomaPatrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses current and emerging immunotherapeutic strategies in melanoma.
Latest:
Treating Advanced-Stage Lung Cancer with TKIsPaul A. Bunn, Jr, MD, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)
Latest:
Episode 11B: The Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC TreatmentIn this companion article, Dr Paul Bunn discuss the implications from the pooled results of trilaciclib on chemotherapy induced myelosuppression (CIM) and reviews management strategies for patients that might develop neutropenia while on chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Latest:
Discussing the Efficacy of a Phase 1/2 Study in R/R CLLPaul Barr, MD, discusses treatment with umbralisib, ublituximab, and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia.
Latest:
Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing CancersPaul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.
Latest:
Closing Thoughts: Richardson on Myeloma Maintenance TherapyPaul Richardson, MD, concludes his conversation by briefly discussing additional trials influencing the multiple myeloma treatment landscape, as well as the use of iberdomide.
Latest:
Surgical Approaches to Gynecologic CancersPaul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at Medstar Washington Hospital Center, discusses how surgical approaches have evolved in gynecologic cancers.
Latest:
Update of VISION Trial Shows Continued Efficacy of Tepotinib in NSCLCPaul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.
Latest:
Dr. Paul Walfish on PD-1 Expression in Thyroid CancerPaul Walfish, MD, professor emeritus at the University of Toronto School of Medicine, senior consult Mount Sinai Hospital discusses programmed death ligand 1 (PD-1) expression in aggressive metastatic papillary thyroid cancer.
Latest:
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRCPaulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Latest:
Barata Addresses Unmet Needs in the Oncology SpacePedro Barata, MD, MSc, FACP, discusses tackling unmet needs in oncology at the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.
Latest:
The Presence of a BRCA Mutation in Patients with Breast CancerPenny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
